Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.

Kannan S, Pantalone KM, Matsuda S, Wells BJ, Karafa M, Zimmerman RS.

J Diabetes. 2016 Mar;8(2):279-85. doi: 10.1111/1753-0407.12301. Epub 2015 Jun 29.

PMID:
25929426
2.

Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.

Hall GC, Smith HT, Curtis B, McMahon AD.

Int J Clin Pract. 2011 May;65(5):586-91. doi: 10.1111/j.1742-1241.2011.02648.x.

PMID:
21489082
3.

Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.

Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S; DREAM investigators.

Diabetes Care. 2010 Oct;33(10):2250-3. doi: 10.2337/dc10-0452. Epub 2010 Jul 13.

4.

Thiazolidinedione associated volume overload and pulmonary hypertension.

Michaelson J.

Ther Adv Cardiovasc Dis. 2008 Dec;2(6):435-8. doi: 10.1177/1753944708093413. Epub 2008 Aug 21. Review.

PMID:
19124440
5.

Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.

Vasudevan AR, Balasubramanyam A.

Diabetes Technol Ther. 2004 Dec;6(6):850-63. Review.

PMID:
15684639
6.

Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.

Wang F, Vergara C, Carabino J, Desilets A, Vasquez R.

Am J Health Syst Pharm. 2004 Aug 1;61(15):1604-8. No abstract available.

PMID:
15372837
7.

Cardiovascular implications of thiazolidinedione therapy.

Lamb RE, King D.

Prog Cardiovasc Nurs. 2004 Summer;19(3):116-22. Review.

PMID:
15249773
8.

Thiazolidinedione-induced congestive heart failure.

Cheng AY, Fantus IG.

Ann Pharmacother. 2004 May;38(5):817-20. Epub 2004 Mar 23.

PMID:
15039476
9.

Considerations for management of fluid dynamic issues associated with thiazolidinediones.

Hollenberg NK.

Am J Med. 2003 Dec 8;115 Suppl 8A:111S-115S. Review.

PMID:
14678876
10.

The patient with diabetes mellitus and heart failure: at-risk issues.

Giles TD.

Am J Med. 2003 Dec 8;115 Suppl 8A:107S-110S. Review.

PMID:
14678875
11.

Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

Mudaliar S, Chang AR, Henry RR.

Endocr Pract. 2003 Sep-Oct;9(5):406-16. Review.

PMID:
14583425
12.

Thiazolidinedione-associated congestive heart failure and pulmonary edema.

Kermani A, Garg A.

Mayo Clin Proc. 2003 Sep;78(9):1088-91.

PMID:
12962163
13.

Do thiazolidinediones cause congestive heart failure?

Kennedy FP.

Mayo Clin Proc. 2003 Sep;78(9):1076-7. No abstract available.

PMID:
12962160
14.

[Precautions for use and contraindications of thiazolidinediones. A cardiologist opinion].

Cohen-Solal A.

Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 2):1S51-5. Review. French.

PMID:
12037510
15.

Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes.

Cheng-Lai A, Levine A.

Heart Dis. 2000 Jul-Aug;2(4):326-33. Review.

PMID:
11728276
16.

The hormone resistin links obesity to diabetes.

Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA.

Nature. 2001 Jan 18;409(6818):307-12.

PMID:
11201732

Supplemental Content

Loading ...
Support Center